AWARD YEAR
2021
CATEGORY
Body
GOALS
Good Health & Well-being, Decent Work & Economic Growth, Industry, Innovation & Infrastructure, Reduced Inequality, Sustainable Cities & Communities
KEYWORDS
ORAL, vaccine, pandemicresponse, covid-19, influenza
COUNTRY
United Kingdom
DESIGNED BY
iosBio Ltd
WEBSITE
https://iosbio.com
Thermally stable, oral Covid-19 vaccine
Thermally stable, orally administered vaccines enable all peoples to take an efficacious vaccine.
iosBio has developed a technology, OraPro, that protects viruses against high temperatures. This means that we enable viral vector vaccines to be taken orally in a capsule or tablet without loss of efficacy during transport through the stomach's 37C to the intestinal tract.
Covid-19 is not a systemic (blood borne, IgG) infection, it infects mucosal cells in the nose, throat and lungs. Unlike injections, which elicit a systemic immune response, oral vaccination produces mucosal immunity (IgA). In a non-human primate trial conducted by Operation Warp Speed, oral vaccination completely cleared infection within 5 days.
Our oral vaccines are needle free and can be transported around the world without an ultra-cold chain (-21C), or even a cold chain (2-8C) raising vaccines availability from the industrialised world's 32%+ to 100% of the world's population.
OraPro is a simple mix of sugars and one chemical, all perfectly safe.
An oral influenza vaccine is in development.